The Global Health Impact Index: Promoting Global Health

about

Correction: The Global Health Impact Index: Promoting Global Health.Individual Responsibility for Promoting Global Health: The Case for a New Kind of Socially Conscious Consumption.

P2860

Q42555205-FB68B09D-F1C5-4848-BBEB-97CEFB0929DA Q47963059-4871F694-7EC7-4E71-A488-ABDBF35C05D3

P2860

The Global Health Impact Index: Promoting Global Health

Item

http://www.wikidata.org/entity/Q28551476

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The Global Health Impact Index: Promoting Global Health

@ast

The Global Health Impact Index: Promoting Global Health

@en

The Global Health Impact Index: Promoting Global Health

@nl

type

Item

label

The Global Health Impact Index: Promoting Global Health

@ast

The Global Health Impact Index: Promoting Global Health

@en

The Global Health Impact Index: Promoting Global Health

@nl

prefLabel

The Global Health Impact Index: Promoting Global Health

@ast

The Global Health Impact Index: Promoting Global Health

@en

The Global Health Impact Index: Promoting Global Health

@nl

P1476

The Global Health Impact Index: Promoting Global Health

@en

P2093

Nicole Hassoun

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries

A new infectious disease model for estimating and projecting HIV/AIDS epidemics.

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.

Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007.

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries

Antiretroviral therapies in women after single-dose nevirapine exposure.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.

P304

e0141374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0141374

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286640159

http://www.w3.org/2001/XMLSchema#string

P698

26657064

http://www.w3.org/2001/XMLSchema#string

P921

global health

P932

4676606

http://www.w3.org/2001/XMLSchema#string

The Global Health Impact Index: Promoting Global Health

about

P2860

P2860

The Global Health Impact Index: Promoting Global Health

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932